Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics

Journal of Clinical Investigation

Volumn 122, Issue 12, 2012, Pages 4314-4322

  Bagni, Claudia ^a,b   Tassone, Flora ^c,d   Neri, Giovanni ^e   Hagerman, Randi ^d,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ARBACLOFEN; BACLOFEN; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; PLACEBO; RO 4917523; STX 069; STX 107; UNCLASSIFIED DRUG; VALPROIC ACID;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; EARLY DIAGNOSIS; FRAGILE X SYNDROME; GENETIC SCREENING; GENETICS; HUMAN; NEUROBIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RNA METABOLISM;

ANIMALS; AUTISTIC DISORDER; EARLY DIAGNOSIS; EPIGENESIS, GENETIC; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MOLECULAR TARGETED THERAPY; SYNAPTIC TRANSMISSION;

EID: 84870543150     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI63141     Document Type: Review

References (137)

1. Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1943;6(3-4):154-157.
2. Coffee B, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85(4):503-514.
3. Hirst MC, Knight SJ, Christodoulou Z, Grewal PK, Fryns JP, Davies KE. Origins of the fragile X syndrome mutation. J Med Genet. 1993;30(8):647-650. (Pubitemid 23246114)
4. Fryns JP, Kleczkowska A, Kubien E, Van den Berghe H. Cytogenetic findings in moderate and severe mental retardation. A study of an institutionalized population of 1991 patients. Acta Paediatr Scand Suppl. 1984;313:1-23.
5. Fu Y-H, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell. 1991;67(6):1047-1058. (Pubitemid 121001519)
6. Verkerk AJ, et al. Intragenic probe used for diagnostics in fragile X families. Am J Med Genet. 1992;43(1-2):192-196.
7. Hagerman R, Au J, Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. J Neurodev Disord. 2011;3(3):211-224.
8. Verkerk AJ, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905-914. (Pubitemid 121001321)
9. Oberle I, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science. 1991;252(5009):1097-1102. (Pubitemid 21917021)
10. Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman PJ, Tassone F. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn. 2009;11(4):306-310.
11. Nolin SL, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet. 2003;72(2):454-464. (Pubitemid 36194253)
12. Yrigollen CM, et al. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet Med. 2012;14(8):729-736.
13. Pietrobono R, et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet. 2005;14(2):267-277.
14. Pieretti M, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817-822. (Pubitemid 121001715)
15. Naumann A, Hochstein N, Weber S, Fanning E, Doerfler W. A distinct DNA-methylation boundary in the 5′- upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet. 2009;85(5):606-616.
16. Malter HE, et al. Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet. 1997;15(2):165-169. (Pubitemid 27061635)
17. Sutcliffe JS, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992;1(6):397-400.
18. Tabolacci E, Moscato U, Zalfa F, Bagni C, Chiurazzi P, Neri G. Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet. 2008;16(12):1487-1498.
19. Kumari D, Usdin K. Interaction of the transcription factors USF1, USF2, and (alpha)-PAL/Nrf-1 with the FMR1 promoter. J Biol Chem. 2001;276(6):4357- 4364.
20. Coffee B, Zhang F, Warren ST, Reines D. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet. 1999;22(1):98-101. (Pubitemid 29214814)
21. Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet. 2000;94(3):232-236.
22. Smeets HJ, et al. Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet. 1995;4(11):2103-2108.
23. Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey. Pediatrics. 2009;124(2):527-533.
24. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord. 2011;3(1):57-67.
25. Sullivan K, et al. ADHD symptoms in children with FXS. Am J Med Genet A. 2006;140(21):2275-2288. (Pubitemid 44684953)
26. Irwin SA, et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet. 2001;98(2):161-167. (Pubitemid 32051804)
27. Carrasco M. [Informing members of families affected by fragile X syndrome of this diagnosis]. Rev Neurol. 2001;33(suppl 1):S37-S41.
28. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet. 2010;19(R1):R83-R89.
29. Cornish KM, et al. The emerging fragile X premutation phenotype: Evidence from the domain of social cognition. Brain Cogn. 2005;57(1):53-60.
30. Bacalman S, et al. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry. 2006;67(1):87-94. (Pubitemid 43213287)
31. Chonchaiya W, et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet. 2012;131(4):581-589.
32. Allingham-Hawkins DJ, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am J Med Genet. 1999;83(4):322-325. (Pubitemid 29162637)
33. Tassone F, et al. Newborn screening in fragile X syndrome: prevalence and allele distribution of the FMR1 gene. Paper presented at: American College of Medical Genetics Annual Clinical Genetics Meeting; July 26, 2012; Charlotte, North Carolina, USA. http://www.fragilex.org/community/international-fragile-x- conference/miami2012/agenda/. Accessed October 19, 2012.
34. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11(4):324-329.
35. Dombrowski C, Levesque ML, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet. 2002;11(4):371-378. (Pubitemid 34213610)
36. Jacquemont S, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra61.
37. Berry-Kravis E, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46(4):266-271.
38. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10(1):43-49. (Pubitemid 351184834)
39. Filipovic-Sadic S, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem. 2010;56(3):399-408.
40. Hantash FM. Fragile X syndrome: is now the time for population screening? MLO Med Lab Obs. 2010;42(5):20, 22.
41. Lyon E, et al. A simple, high-throughput assay for Fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. J Mol Diagn. 2010;12(4):505-511.
42. Godler DE, Slater HR, Amor D, Loesch DZ. Methylation analysis of fragile X-related epigenetic elements may provide a suitable newborn screening test for fragile X syndrome. Genet Med. 2010;12(9):595.
43. Coffee B. Commentary on population screening for fragile X syndrome. Genet Med. 2010;12(7):411-412.
44. Xuncla M, et al. Fragile X syndrome prenatal diagnosis: parental attitudes and reproductive responses. Reprod Biomed Online. 2010;21(4):560-565.
45. McDuffie A, et al. Autism spectrum disorder in children and adolescents with fragile X syndrome: within-syndrome differences and age-related changes. Am J Intellect Dev Disabil. 2010;115(4):307-326.
46. Hatton DD, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A. 2006;140A(17):1804-1813. (Pubitemid 44330644)
47. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol. 2002;44(11):724-728. (Pubitemid 35230036)
48. Garcia-Nonell C, et al. Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. Am J Med Genet A. 2008;146A(15):1911-1916.
49. Meguid NA, et al. Cognition and lobar morphology in full mutation boys with fragile X syndrome. Brain Cogn. 2012;78(1):74-84.
50. Dawson G, Hessl D, Frey K. Social influences on early-developing biological and behavioral systems related to risk for affective disorder. In: Cicchetti D, Tucker, eds. Special Issue of Development and Psychopathology on "Neural plasticity, sensitive periods and psychopathology." 1995;6:759-780.
51. Dawson G, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics. 2010;125(1):e17-e23.
52. Napoli I, et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell. 2008;134(6):1042-1054.
53. Nishimura Y, et al. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet. 2007;16(14):1682-1698. (Pubitemid 47241828)
54. van der Zwaag B, et al. A co-segregating microduplication of chromosome 15q11.2 pinpoints two risk genes for autism spectrum disorder. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(4):960-966.
55. Leblond CS, et al. Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet. 2012;8(2):e1002521.
56. Schellenberg GD, et al. Evidence for multiple loci from a genome scan of autism kindreds. Mol Psychiatry. 2006;11(11):1049-1060, 1979.
57. Neves-Pereira M, et al. Deregulation of EIF4E: a novel mechanism for autism. J Med Genet. 2009;46(11):759-765.
58. Darnell JC, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146(2):247-261.
59. Eberhart DE, Malter HE, Feng Y, Warren ST. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet. 1996;5(8):1083-1091. (Pubitemid 26318545)
60. Sittler A, Devys D, Weber C, Mandel JL. Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of fmr1 protein isoforms. Hum Mol Genet. 1996;5(1):95-102. (Pubitemid 26018279)
61. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci. 2005;6(5):376-387. (Pubitemid 40593483)
62. De Rubeis S, Fernandez E, Buzzi A, Di Marino D, Bagni C. Molecular and Cellular Aspects of Mental Retardation in the Fragile X Syndrome: From Gene Mutation/s to Spine Dysmorphogenesis. Adv Exp Med Biol. 2012;970:517-551.
63. Wang T, Bray SM, Warren ST. New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev. 2012;22(3):256-263.
64. Anderson P, Kedersha N. RNA granules. J Cell Biol. 2006;172(6):803-808.
65. Brown V, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107(4):477-487. (Pubitemid 33152783)
66. Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience. 2003;120(4):1005-1017. (Pubitemid 36969801)
67. Miyashiro KY, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37(3):417-431. (Pubitemid 36183364)
68. Bakker CE, et al. FMR1 knockout mice: A model to study fragile X mental retardation. Cell. 1994;78(1):23-33. (Pubitemid 24228297)
69. Zalfa F, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003;112(3):317-327. (Pubitemid 36183653)
70. Zalfa F, et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci. 2007;10(5):578-587. (Pubitemid 46652449)
71. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci. 2007;27(20):5338-5348. (Pubitemid 46790157)
72. Narayanan U, et al. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J Biol Chem. 2008;283(27):18478-18482.
73. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007;5(3):e52.
74. Lacoux C, et al. BC1-FMRP interaction is modulated by 2′-O-methylation: RNA-binding activity of the tudor domain and translational regulation at synapses. Nucleic Acids Res. 2012;40(9):4086-4096.
75. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370-377. (Pubitemid 38829251)
76. Centonze D, et al. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry. 2008;63(10):963-973. (Pubitemid 351602272)
77. Gatto CL, Broadie K. Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models. Front Synaptic Neurosci. 2010;2:4.
78. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002;99(11):7746-7750. (Pubitemid 34568762)
79. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A. 2007;104(39):15537-15542. (Pubitemid 47502952)
80. Curia G, Papouin T, Seguela P, Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex. 2009;19(7):1515-1520.
81. Shang Y, Wang H, Mercaldo V, Li X, Chen T, Zhuo M. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. J Neurochem. 2009;111(3):635-646.
82. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A. 2010;107(25):11591-11596.
83. Eadie BD, Cushman J, Kannangara TS, Fanselow MS, Christie BR. NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice. Hippocampus. 2012;22(2):241-254.
84. Yun SH, Trommer BL. Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus. J Neurosci Res. 2011;89(2):176-182.
85. Louhivuori V, et al. BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse. Neurobiol Dis. 2011;41(2):469-480.
86. Nalavadi VC, Muddashetty RS, Gross C, Bassell GJ. Dephosphorylation- induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation. J Neurosci. 2012;32(8):2582-2587.
87. Hoeffer CA, et al. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 2012;11(3):332-341.
88. Kim SH, Markham JA, Weiler IJ, Greenough WT. Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc Natl Acad Sci U S A. 2008;105(11):4429-4434. (Pubitemid 351754397)
89. Sharma A, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci. 2010;30(2):694-702.
90. Dolen G, et al. Correction of fragile X syndrome in mice. Neuron. 2007;56(6):955-962. (Pubitemid 350251119)
91. Westmark CJ, et al. Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS One. 2011;6(10):e26549.
92. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480(7375):63-68.
93. Hayashi ML, et al. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A. 2007;104(27):11489-11494. (Pubitemid 47175167)
94. Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 2012;11(5):586-600.
95. Chiurazzi P, Pomponi MG, Willemsen R, Oostra BA, Neri G. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet. 1998;7(1):109-113. (Pubitemid 28040744)
96. Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet. 1999;8(12):2317-2323. (Pubitemid 29525348)
97. Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet. 2005;13(5):641-648. (Pubitemid 40691406)
98. Pomponi MG, Neri G. Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro. Am J Med Genet. 1994;51(4):447-450. (Pubitemid 24197720)
99. Torrioli MG, et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet. 1999;87(4):366-368.
100. Torrioli MG, et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008;146(7):803-812. (Pubitemid 351499783)
101. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276(39):36734-36741.
102. Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem. 2003;278(30):27586-27592. (Pubitemid 36899944)
103. Tabolacci E, et al. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics. 2008;18(8):738-741.
104. Torrioli M, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A. 2010;152A(6):1420-1427.
105. Berry-Kravis E, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006;16(5):525-540. (Pubitemid 44737208)
106. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005;49(7):1053-1066. (Pubitemid 41503304)
107. Su T, et al. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology (Berl). 2011;215(2):291-300.
108. Michalon A, et al. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice. Neuron. 2012;74(1):49-56.
109. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol. 1982;2(2):129-133. (Pubitemid 12025672)
110. Novartis. Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients. NIH Web site. http://clinicaltrials.gov/ct2/show/NCT00718341. Updated May 5, 2010. Updated October 19, 2012.
111. Hoffmann-La Roche. A Study With RO4917523 in Patients With Fragile X Syndrome. NIH Web site. http://clinicaltrials.gov/ct2/show/NCT01015430?term= RO4917523&rank=4. Updated December 5, 2011. Accessed October 19, 2012.
112. Seaside Therapeutics, Inc. A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107. NIH Web site. http://clinicaltrials.gov/ct2/show/NCT00965432?term=STX107&rank=2. Updated February 5, 2010. Accessed October 19, 2012.
113. D'Hulst C, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006;1121(1):238-245. (Pubitemid 44708899)
114. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci. 2010;30(29):9929-9938.
115. Erickson CA, Mullett JE, McDougle CJ. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord. 2010;40(11):1412-1416.
116. Hagerman RJ, Hessl D, Rogawski M. A Controlled Double-Blind Cross-over Trial of Ganaxolone in Children with Fragile X Syndrome. Marinus Web site. http://www.marinuspharma.com/collaborators.html. Accessed October 19, 2012.
117. Pacey LK, Heximer SP, Hampson DR. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol. 2009;76(1):18-24.
118. Berry-Kravis EM, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, Phase 2 trial. Sci Transl Med. 2012;4(152):152ra127.
119. Seaside Therapeutics, Inc. Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome. NIH Web site. http://clinicaltrials. gov/ct2/show/NCT00788073?term=berry-kravis&rank=3. Updated September 28, 2012. Accessed October 19, 2012.
120. Seaside Therapeutics, Inc. A Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C). NIH Web site. http://clinicaltrials.gov/ct2/show/NCT01325220?term=baclofen+and+fragile+x& rank=1. Updated October 10, 2012. Accessed October 19, 2012.
121. Min WW, et al. Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology. 2009;56(2):463-472.
122. Berry-Kravis E, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29(4):293-302.
123. Bilousova TV, Rusakov DA, Ethell DW, Ethell IM. Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J Neurochem. 2006;97(1):44-56.
124. Imbesi M, Uz T, Manev R, Sharma RP, Manev H. Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci Lett. 2008;447(2-3):134-137.
125. Bilousova TV, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009;46(2):94-102.
126. Utari A, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil. 2010;115(5):433-443.
127. Paribello C. Open label add on treatment trial of minocycline in patients with fragile X syndrome. BMC Neurol. 2010;10:91.
128. Hagerman RJ. Trial of Minocycline to Treat Children With Fragile X Syndrome. NIH Web site. http://clinicaltrials.gov/ct2/show/NCT01053156?term= minocycline+and+fragile+x&rank=1. Updated April 10, 2012. Accessed October 19, 2012.
129. Restivo L, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A. 2005;102(32):11557-11562. (Pubitemid 41153858)
130. Meredith RM, Holmgren CD, Weidum M, Burnashev N, Mansvelder HD. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. Neuron. 2007;54(4):627-638. (Pubitemid 46756139)
131. Moskowitz LJ, Carr EG, Durand VM. Behavioral intervention for problem behavior in children with fragile X syndrome. Am J Intellect Dev Disabil. 2011;116(6):457-478.
132. Turk J. Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability. Curr Opin Psychiatry. 2011;24(5):387-397.
133. Braden M. Classroom adaptations: good practice and work habits. In: Dew-Hughes D, ed. Educating Children With Fragile X Syndrome: A Miltiprofessional View. New York, New York, USA: Routledge-Falmer; 2004:83-96.
134. Dyer-Friedman J, et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41(3):237-244. (Pubitemid 38338144)
135. Hessl D, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics. 2001;108(5):E88.
136. Callan MA, Zarnescu DC. Heads-up: new roles for the fragile X mental retardation protein in neural stem and progenitor cells. Genesis. 2011;49(6):424-440.
137. Narayanan U, et al. FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J Neurosci. 2007;27(52):14349-14357.